翰思艾泰生物医药科技（武汉）股份有限公司（翰思艾泰-B，股票代码：03378）于2026年4月17日发布公告，披露其在香港联合交易所场内回购普通股H股共23,000股，占公司已发行股本约0.017%。本次回购股份的价格区间介乎每股28.8港元至30.8港元，合共涉资约68.46万港元。
本次回购完成后，公司已发行股份由原先的135,997,930股减少至135,974,930股，同时库藏股数增至243,900股，合计股本仍为136,218,830股。公告显示，该回购行为依据2026年2月12日通过的购回授权进行，该授权允许公司最多回购13,621,883股股份。截至目前，公司累计购回243,900股，占购回授权通过当日已发行股本的0.1791%。
公司在公告中确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。本次公告由董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.